Provention Bio Inc PRVB

NAS: PRVB | ISIN: US74374N1028   26/04/2023
24,98 USD (+3,10%)
(+3,10%)   26/04/2023

13 maart 2023 · Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call · Persbericht

3 maart 2023 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

23 februari 2023 · Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 · Persbericht

13 februari 2023 · Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US · Persbericht

8 februari 2023 · Provention Bio to Present at the SVB Securities Global Biopharma Conference · Persbericht

3 februari 2023 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

2 februari 2023 · Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD® · Persbericht

6 januari 2023 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

5 januari 2023 · Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors · Persbericht

2 december 2022 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

17 november 2022 · TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D · Persbericht

4 november 2022 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

3 november 2022 · Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update · Persbericht

13 oktober 2022 · Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022 · Persbericht

7 oktober 2022 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

6 oktober 2022 · Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals · Persbericht

19 september 2022 · Provention Bio Announces Senior Leadership Addition · Persbericht

6 september 2022 · Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference · Persbericht

2 september 2022 · Provention Bio Announces the Grant of Inducement Awards · Persbericht

1 september 2022 · Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital · Persbericht

Mijn selecties